Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study

Reactivation of Multiple Sclerosis (MS) activity has been described after fingolimod cessation. Because of its contra indication during pregnancy, switch towards lower efficacy treatments are frequent in MS patients with childbearing desire but expose them to a risk of disease reactivation. In this...

Full description

Saved in:
Bibliographic Details
Published inMultiple sclerosis and related disorders Vol. 66; p. 104066
Main Authors Callens, Alix, Leblanc, Soline, Le Page, Emmanuelle, Edan, Gilles, Jourdain, Aurore, Coustans, Marc, Wiertlewski, Sandrine, Laplaud, David, Videt, Dorothée, Lallement, Francois, Leray, Emmanuelle, Michel, Laure
Format Journal Article
LanguageEnglish
Published Elsevier B.V 01.10.2022
Elsevier
Subjects
Fingolimod-disease reactivation
Life Sciences
Multiple Sclerosis
Pregnancy desire
Santé publique et épidémiologie
Multiple Sclerosis
Pregnancy desire
Fingolimod-disease reactivation
Online AccessGet full text

Cover

More Information
Summary:Reactivation of Multiple Sclerosis (MS) activity has been described after fingolimod cessation. Because of its contra indication during pregnancy, switch towards lower efficacy treatments are frequent in MS patients with childbearing desire but expose them to a risk of disease reactivation. In this retrospective study including 44 women with MS, a significant increase of the median annualized relapse rate was found in the year following fingolimod discontinuation compared to the period before (p < 0.0001), and 57% of women experienced at least one relapse. When considering to start fingolimod, particular attention should be paid to women with a short-term pregnancy desire.
Bibliography:SourceType-Other Sources-1
content type line 63
ObjectType-Correspondence-1
ISSN:2211-0348
2211-0356
2211-0356
2211-0348
DOI:10.1016/j.msard.2022.104066